Ten numbers in the abstract
Where each one falls
Where it lands on the map
the abstract, start to end
… a lower risk of cancer incidence (RR = 0.86, 95% CI 0.83-0.90, I(2) = 88.61%; RR = 0.93, 95% CI 0.91-0.96, I(2) = 0.00% …
… increased risk of cancer incidence (RR = 1.21, 95% CI 1.08-1.36, I(2) = 96.31%; RR = 1.20, 95% CI 1.13-1.27, I(2) = 95.02%; RR = 1.10, 95% CI 1.05-1.15, I(2) = 0.00% …
… with the risk of cancer (7 studies, RR = 0.90, 95% CI 0.49-1.65) (Table 1i).
… risk of cancer (72 studies, RR = 1.20, 95% CI 1.13-1.27) (Table 1c).
… risk of cancer (73 studies; RR = 1.21, 95% CI 1.08-1.36) (Table 1a).
… risk of cancer (13 studies, RR = 1.10, 95% CI 1.05-1.15) (Table 2f).
… associated with the risk of cancer (RR = 0.92, 95% CI 0.82-1.04) (Table 1e).
← favours treatmentfavours comparator →
could be chanceAdverse events & safety
RR 0.860.83–0.90
Adverse events & safety
RR 0.930.91–0.96
Glycemic control
RR 1.211.08–1.36
Glycemic control
RR 1.201.13–1.27
Glycemic control
RR 1.101.05–1.15
Adverse events & safety
RR 0.900.49–1.65
Adverse events & safety
RR 1.201.13–1.27
Glycemic control
RR 1.211.08–1.36
Adverse events & safety
RR 1.101.05–1.15
Adverse events & safety
RR 0.920.82–1.04
MetforminSGLT2 inhibitorsGLP-1 receptor agonistsDPP-4 inhibitorsSulfonylureas & glinidesThiazolidinedionesInsulinOther glucose-loweringGlycemic controlAdverse events & safety
1 / 3